Autologous stem cell transplant in recurrent or refractory primary or secondary central nervous system lymphoma using thiotepa, busulfan and cyclophosphamide Journal Article


Authors: Welch, M. R.; Sauter, C. S.; Matasar, M. J.; Faivre, G.; Weaver, S. A.; Moskowitz, C. H.; Omuro, A. M.
Article Title: Autologous stem cell transplant in recurrent or refractory primary or secondary central nervous system lymphoma using thiotepa, busulfan and cyclophosphamide
Abstract: The prognosis for patients with central nervous system (CNS) involvement by recurrent or refractory diffuse large B-cell lymphoma is poor, with overall survival (OS) of 4-10 months. High-dose chemotherapy (HDC) and autologous stem cell transplant (ASCT) is a potential treatment alternative. We reviewed patients with recurrent primary (PCNSL) or secondary (SCNSL) CNS lymphoma referred for consolidation HDC-ASCT utilizing thiotepa, busulfan and cyclophosphamide (TBC). Among the 17 patients included, all had achieved a complete remission after salvage induction chemotherapy, which incorporated methotrexate in 82% of patients. Two patients failed stem-cell harvesting and 15 (88%) underwent transplant. The estimated 3-year progression-free survival (PFS) and OS were both 93% (95% confidence interval 61-99%). Median PFS and OS were not reached. There was no transplant-related mortality. These results confirm the benefit of TBC followed by ASCT in select patients with recurrent PCNSL and suggest a potential role for the regimen in those with SCNSL. Further investigation is warranted. © 2014 Informa UK, Ltd.
Keywords: adult; cancer chemotherapy; cancer survival; clinical article; middle aged; overall survival; busulfan; prednisone; fatigue; cancer recurrence; doxorubicin; diarrhea; treatment duration; cancer patient; cancer radiotherapy; primary central nervous system lymphoma; cytarabine; methotrexate; rituximab; temozolomide; drug megadose; carboplatin; progression free survival; etoposide; mucosa inflammation; cyclophosphamide; melphalan; vincristine; autologous stem cell transplantation; retrospective study; cancer therapy; cancer mortality; carmustine; ifosfamide; procarbazine; thiotepa; central nervous system tumor; febrile neutropenia; cancer regression; stem cell mobilization; colitis; mesna; granulocyte colony stimulating factor; plerixafor; induction chemotherapy; pericarditis; autologous stem cell transplant; high-dose chemotherapy; central nervous system lymphoma; consolidation chemotherapy; chemotherapeutic approaches; human; male; female; priority journal; article; secondary central nervous system lymphoma
Journal Title: Leukemia and Lymphoma
Volume: 56
Issue: 2
ISSN: 1042-8194
Publisher: Taylor & Francis Group  
Date Published: 2015-02-01
Start Page: 361
End Page: 367
Language: English
DOI: 10.3109/10428194.2014.916800
PROVIDER: scopus
PUBMED: 24745937
DOI/URL:
Notes: Export Date: 2 April 2015 -- Source: Scopus
Altmetric
Citation Impact
MSK Authors
  1. Craig Moskowitz
    392 Moskowitz
  2. Antonio Marcilio Padula Omuro
    195 Omuro
  3. Mary Welch
    11 Welch
  4. Craig Steven Sauter
    211 Sauter
  5. Sarah A Weaver
    6 Weaver
  6. Matthew J Matasar
    158 Matasar
  7. Geraldine M Faivre
    7 Faivre